查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2021040

標靶α射線療法的全球市場規模、監管核准、專有技術、治療應用和臨床試驗見解（2030年）

Global Targeted Alpha Therapy Market Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications & Clinical Trials Insight 2030
出版日期: | 出版商: KuicK Research | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

全球標靶α療法市場規模、監管核准、專有技術、治療應用和臨床試驗洞察－2030年報告的主要發現和亮點：

  • 區域及全球標靶α療法市場展望
  • 當前市場概況和未來成長領域
  • 目前正在進行臨床試驗的標靶α射線療法數量：超過30種藥物
  • 依公司、適應症和階段分析標靶α盲法治療臨床試驗的見解。
  • 對已通過核准的標靶α放射療法的劑量和定價的深入了解
  • 針對標靶α療法專有技術平台進行逐家公司分析
  • 根據癌症類型應用標靶α放射療法
  • 競爭格局

標靶α射線治療的必要性及本報告的意義

標靶α放射療法是一種創新的癌症治療技術，它利用α發射同位素的高線性能量轉移特性，在不傷害正常組織的情況下，特異性靶向癌細胞。與其他治療方法相比，標靶α放射療法具有更高的特異性和療效，並且有可能克服抗藥性機制，使其成為治療轉移性和抗藥性癌症的理想選擇。鑑於其他放射源和傳統治療方法的不足，標靶治療的開發至關重要，而標靶α放射療法作為一種未來的癌症治療技術，正備受關注。

目前，全球標靶α粒子發射療法市場正經歷快速成長，多種α粒子發射材料，例如錒-225、砹-211和鉛-212，到2026年將進入不同的臨床階段。此外，一些治療方案在早期研發階段就已顯示出強大的抗腫瘤活性，並有可能幫助解決與攝護腺癌和肝細胞癌相關的問題。

報告中包含對臨床試驗的深入分析

臨床開發仍是標靶α射線治療市場擴張的關鍵驅動力。本說明詳細介紹了從I期到III期各個階段的臨床試驗，重點關注目標患者群體、給藥方法、藥物組合和結果。例如，ALPHAMEDIX02進行了一項II期臨床試驗，研究212Pb-DOTAMTATE治療胃腸道和胰臟神經內分泌腫瘤的療效，即使在先前接受過BETA射線治療的患者中，也取得了60%的高緩解率。早期使用砹-211的試驗也證實了其在治療復發性甲狀腺惡性腫瘤的有效性。

本報告還涵蓋了聯合治療，這些療法透過將標靶α射線療法與雄激素受體拮抗劑、化療藥物或免疫療法相結合來增強抗腫瘤效果。本報告提供的資訊可用於評估這些療法的科學性和商業可行性。

引領標靶α粒子療法研發的主要企業

標靶α粒子增亮療法的發展趨勢涵蓋了製藥業的老字型大小企業新興企業。例如，Actinium Pharmaceuticals、Orano Med、NAYA Therapeutics和Fusion Pharma等公司正在開發前沿治療方法，而NAYA與中國Alpha Nuclide公司在砹-211生產方面的策略夥伴關係，凸顯了國際物流和可擴展生產流程的重要性。

此外，併購活動持續影響競爭格局，例如阿斯特捷利康收購Fusion Pharmaceuticals以及百時美施貴寶收購RayzeBio。這些併購措施旨在取得TAT技術、拓展產品線並確保同位素的穩定供應。

技術平台和戰略洞察

本報告深入分析了標靶α射線療法生產中使用的各項技術，包括相關平台、製程以及該領域的最新創新成果。研究指出了一些關鍵推動因素，例如利用迴旋加速器生產錒-225以及透過化學方法提取鉛-212。報告也涵蓋了標靶α射線療法在治療診斷學、即時影像和腫瘤學方面的發展趨勢。

標靶α粒子療法的未來前景

標靶α放射治療產業潛力巨大，眾多成功案例為其發展提供了有力支撐。技術的進步以及標靶α放射治療在腫瘤學以外的應用不斷拓展，預示著它將成為未來精準醫療的基石。本報告為相關人員提供了關於新興機會、競爭格局和技術差異化的寶貴見解，這對於在這個快速發展的治療領域做出明智的決策至關重要。

目錄

第1章：調查方法

第2章：標靶α粒子熱療簡介

  • 概述
  • 癌症治療中α射線與BETA/γ射線的比較

第3章 標靶α粒子熱療－結構與作用機制

  • 結構
  • 作用機制

第4章：標靶α粒子療法在癌症治療的應用

  • 骨髓惡性腫瘤
  • 固態腫瘤

第5章：全球標靶α療法市場概覽

  • 當前市場狀況
  • 未來成長路徑

第6章：區域標靶α療法市場洞察

  • 美國
  • 歐洲
  • 中國
  • 日本
  • 澳洲

第7章 全球標靶α熱療臨床試驗概述

  • 步步
  • 公司
  • 適應症

第8章：依公司、適應症和階段分類的標靶α熱療臨床試驗概況

  • 臨床前
  • 第一階段
  • 第一/二期
  • 第二階段
  • 第二/三期
  • 第三階段

第9章 按公司、國家和適應症分類的市售標靶α療法的臨床研究結果

第10章：佐菲戈－首個核准的標靶α射線療法

  • 概述和專利考量
  • 價格和劑量

第11章 標靶α療法－公司特有的專有技術平台

第12章：全球標靶α療法市場動態

  • 促進者和機會
  • 挑戰和限制因素

第13章 競爭格局

  • Actinium Pharma
  • AdvanCell
  • Ariceum Therapeutics
  • Bayer
  • Fusion Pharma
  • Orano Med
  • Perspective Therapeutics
  • RadioMedix
  • RayzeBio
  • Telix Pharmaceuticals

Global Targeted Alpha Therapy Market Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications & Clinical Trials Insight 2030 Report findings & Highlights:

  • Global Targeted Alpha Therapy Market Outlook By Region
  • Current Market Overview & Future Growth Avenues
  • Number Of Targeted Alpha Therapy In Clinical Trials: > 30 Drugs
  • Targeted Alpha Therapy Clinical Trials Insight By Company, Indication & Phase
  • Dosage & Pricing insight On Approved Targeted Alpha Therapy
  • Targeted Alpha Therapy Proprietary Technology Platform Insights By Company
  • Targeted Alpha Therapy Applications By Cancer
  • Competitive Landscape

Need For Targeted Alpha Therapies & Why This Report?

Targeted Alpha Therapies represent an innovative technique in cancer treatment that utilizes the high linear energy transfer characteristic of alpha emitting isotopes to specifically target cancerous cells without damaging normal tissue. In contrast to other treatment modalities, Targeted Alpha Therapies provide specificity, efficacy, and the potential to circumvent resistance pathways, thus making them ideal for the treatment of metastatic and drug-resistant cancers. The shortcomings of other radiation emitters and traditional treatments have rendered the development of targeted therapies critical, placing Targeted Alpha Therapies in the spotlight for future cancer therapy techniques.

The global market or targeted alpha therapies is currently experiencing rapid growth due to the advancement of several alpha emitters, such as Actinium-225, Astatine-211, and Lead-212, through various clinical stages in 2026. In addition to this, there are already several therapeutic solutions that showed strong anti-tumor activity in the initial stages of development and can help in dealing with problems related to prostate cancer and hepatocellular carcinoma.

Clinical Trials Insight Included In Report

Clinical development continues to be an important factor behind the expansion of the Targeted Alpha Therapies market. In this report, we discuss various trials at different phases, from Phase I to Phase III, focusing on demographics, dosing regimens, drug combinations, and results. As an example, ALPHAMEDIX02 conducted a Phase II trial for the treatment of gastroenteropancreatic neuroendocrine tumors with 212Pb-DOTAMTATE, which yielded response rates as high as 60% even for patients that had been administered beta-emitting agents previously. Initial trials with Astatine-211 have also proved effective in treating recurrent thyroid malignancies.

Combination therapies are also covered in this report where Targeted Alpha Therapies have been combined with androgen receptor antagonists, chemotherapeutic agents, or immunotherapy to boost antitumor efficacy. With the help of the information provided in this report, it is possible to make an evaluation regarding both scientific and business viability.

Major Companies Driving Targeted Alpha Therapy R&D

The development landscape of targeted alpha therapies comprises of both mature players in the pharmaceutical industry and emerging players. Examples include companies like Actinium Pharmaceuticals, Orano Med, NAYA Therapeutics, and Fusion Pharma that are developing cutting-edge treatments, whereas strategic partnerships, like NAYA's alliance with Alpha Nuclide in China to produce Astatine-211, emphasize the significance of international logistics and scalable manufacturing processes.

There are also merger and acquisition activities that continue to shape the competition environment as seen by the recent acquisition of Fusion Pharmaceuticals by AstraZeneca and the acquisition of RayzeBio by Bristol Myers Squibb. Such mergers and acquisitions represent strategies geared towards gaining access to TAT technology, expanding the pipeline, and ensuring consistent access to isotopes.

Technology Platforms & Strategic Insights Offered

This report offers an insightful analysis of the technologies used in Targeted Alpha Therapies manufacturing, including the platform and processes involved, and the latest innovations in this domain. The study identifies some critical enabling factors such as the process of generating Actinium-225 from a cyclotron and the extraction of Lead-212 through chemistry. The report also captures the trends within the Targeted Alpha Therapy theranostics, real-time imaging, and oncology domains.

Future Outlook For Targeted Alpha Therapy

There is a lot of potential in the targeted alpha therapy industry, and that has been fueled by several successes in the area. As a result of advancements in technology and the broadening scope of Targeted Alpha Therapy applications outside of oncology, it is set to be one of the pillars of precision medicine in the future. By utilizing this report, stakeholders can obtain valuable insights about new opportunities, competitive position, and technology differentiators that are essential for making an informed decision in the ever-changing therapeutic field.

Table of Contents

1. Research Methodology

2. Introduction To Targeted Alpha Therapy

  • 2.1 Overview
  • 2.2 Alpha Radiation vs. Beta & Gamma Radiation In Cancer Therapy

3. Targeted Alpha Therapy - Structure & Mechanism Of Action

  • 3.1 Structure
  • 3.2 Mechanism Of Action

4. Targeted Alpha Therapy Applications By Cancer

  • 4.1 Hematological Malignancies
  • 4.2 Solid Tumors

5. Global Targeted Alpha Therapy Market Insight

  • 5.1 Current Market Scenario
  • 5.2 Future Growth Avenues

6. Targeted Alpha Therapy Market Insight By Region

  • 6.1 US
  • 6.2 Europe
  • 6.3 China
  • 6.4 Japan
  • 6.5 Australia

7. Global Targeted Alpha Therapy Clinical Trials Overview

  • 7.1 By Phase
  • 7.2 By Company
  • 7.3 By Indication

8. Targeted Alpha Therapy Clinical Trials Insight By Company, Indication & Phase

  • 8.1 Preclinical
  • 8.2 Phase I
  • 8.3 Phase I/II
  • 8.4 Phase II
  • 8.5 Phase II/III
  • 8.6 Phase III

9. Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication

10. Xofigo - 1st Approved Targeted Alpha Therapy

  • 10.1 Overview & Patent Insight
  • 10.2 Pricing & Dosing

11. Targeted Alpha Therapy - Proprietary Technology Platform By Company

12. Global Targeted Alpha Therapy Market Dynamics

  • 12.1 Drivers & Opportunities
  • 12.2 Challenges & Restraints

13. Competitive Landscape

  • 13.1 Actinium Pharma
  • 13.2 AdvanCell
  • 13.3 Ariceum Therapeutics
  • 13.4 Bayer
  • 13.5 Fusion Pharma
  • 13.6 Orano Med
  • 13.7 Perspective Therapeutics
  • 13.8 RadioMedix
  • 13.9 RayzeBio
  • 13.10 Telix Pharmaceuticals

List of Figures

  • Figure 3-1: Targeted Alpha Therapy - Structure
  • Figure 3-2: Targeted Alpha Therapy - Mechanism Of Action
  • Figure 4-1: LIN-AC225-AML02 Phase 1/2 (NCT03867682) Study - Initiation & Completion Year
  • Figure 4-2: RG1121028 Phase 1 (NCT04579523) Study - Initiation & Completion Year
  • Figure 4-3: 225Ac-DOTA-daratumumab Phase 1 (NCT05363111) Study - Initiation & Completion Year
  • Figure 4-4: PAnTHA Phase 1 (NCT06217822) Study - Initiation & Completion Year
  • Figure 4-5: 2022-502623-22-00 Phase 1 (NCT06052306) Study - Initiation & Completion Year
  • Figure 4-6: TheraPb Phase I/II (NCT05720130) Study - Initiation & Completion Year
  • Figure 4-7: VMT-a-NET-T101 Phase I/II (NCT05636618) Study - Initiation & Completion Year
  • Figure 4-8: ALPHAMEDIX02 Phase II (NCT05153772) Study - Initiation & Completion Year
  • Figure 5-1: Factors Influencing Future Market of Targeted Alpha Therapies
  • Figure 5-2: Global - Targeted Alpha Therapy Market Opportunity (US$ Million), 2026 & 2030
  • Figure 7-1: Global - - Number Of Targeted Alpha Therapy Clinical Pipeline By Phase, 2026
  • Figure 7-2: Global - - Number Of Targeted Alpha Therapy Clinical Pipeline By Company, 2026
  • Figure 7-3: Global - - Number Of Targeted Alpha Therapy Clinical Pipeline By Indication, 2026
  • Figure 11-1: Fusion Pharma - Fast-Clear(TM) Linker Technology
  • Figure 11-2: AdvanCell - Proprietary 212Pb Production Technology
  • Figure 11-3: Cellectar Biosciences - Phospholipid Ether (PLE) Platform Technology
  • Figure 11-4: Perspective Therapeutics - Proprietary Technology & Pb-212 Isotope Generator VMT-a-NET
  • Figure 12 1: Global Targeted Alpha Therapy Market - Drivers & Opportunities
  • Figure 12 2: Global Targeted Alpha Therapy Market - Challenges & Restraints

List of Tables

  • Table 2-1: Alpha Radiation vs. Beta & Gamma Radiation In Cancer Therapy
  • Table 8-1: Targeted Alpha Therapies In Preclinical Stage, 2026
  • Table 8-2: Targeted Alpha Therapies In Phase I, 2026
  • Table 8-3: Targeted Alpha Therapies In Phase I/II, 2026
  • Table 8-4: Targeted Alpha Therapies In Phase II, 2026
  • Table 8-5: Targeted Alpha Therapies In Phase II/III, 2026
  • Table 8-6: Targeted Alpha Therapies In Phase III, 2026
  • Table 9-1: Marketed Targeted Alpha Therapies, 2026
  • Table 10-1: Xofigo - Decay Correction Factor